Eton Pharmaceuticals (NASDAQ:ETON) Stock Crosses Above 50 Day Moving Average – Here’s What Happened

Eton Pharmaceuticals, Inc. (NASDAQ:ETON)’s share price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $54.80 and traded as high as $58.59. Eton Pharmaceuticals shares last traded at $56.46, with a volume of 1,269,987 shares.

Key Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Analysts Set New Price Targets

Several equities analysts recently weighed in on ETON shares. Craig Hallum restated a “buy” rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a report on Thursday, October 15th. B. Riley Financial reissued a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. HC Wainwright raised their target price on Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday. Finally, Canaccord Genuity Group boosted their price target on shares of Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $77.00.

Eton Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.61 billion, a PE ratio of 37.39 and a beta of 0.89. The company’s fifty day simple moving average is $54.80 and its 200 day simple moving average is $36.46. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. The business had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. As a group, equities research analysts expect that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other news, Director Paul V. Maier sold 50,000 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider David Krempa sold 4,166 shares of Eton Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total value of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares of the company’s stock, valued at approximately $2,388,991.67. This trade represents a 8.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 79,166 shares of company stock worth $4,809,672 in the last 90 days. 16.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds have recently modified their holdings of the business. JW Asset Management LLC acquired a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $690,000. Russell Investments Group Ltd. raised its position in shares of Eton Pharmaceuticals by 296.3% during the third quarter. Russell Investments Group Ltd. now owns 32,362 shares of the company’s stock worth $1,666,000 after purchasing an additional 24,195 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $240,000. Kornitzer Capital Management Inc. KS acquired a new stake in Eton Pharmaceuticals in the third quarter worth about $830,000. Finally, Pictet Asset Management Holding SA bought a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $226,000. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.